Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, School of Medicine, Atlanta, GA, USA.
Blood. 2010 Dec 9;116(24):5285-8. doi: 10.1182/blood-2010-03-272393. Epub 2010 Sep 15.
In this report, we investigated the mechanism responsible for synergistic induction of myeloma cell apoptosis induced by the combination of tipifarnib and bortezomib. Immunofluorescence studies revealed that bortezomib alone resulted in an accumulation of puncta of ubiquitinated proteins that was further enhanced by the addition of tipifarnib. These data suggest inhibition of the degradation of bortezomib-induced aggresomes; and consistent with this possibility, we also observed an increase in p62SQSTM1 in cells treated with the combination. However, autophagy in these cells appears to be normal as LC3BII is present, and autophagic flux appears to be unaffected as demonstrated by the addition of bafilomycin A₁. Together, these data demonstrate that tipifarnib synergizes with bortezomib by inducing protein accumulation as a result of the uncoupling of the aggresome and autophagy pathways.
在本报告中,我们研究了替皮芬尼与硼替佐米联合诱导骨髓瘤细胞凋亡的协同作用机制。免疫荧光研究显示,硼替佐米单独作用会导致泛素化蛋白斑点的积累,而替皮芬尼的加入则进一步增强了这种积累。这些数据表明,替皮芬尼抑制了硼替佐米诱导的聚集物的降解;并且与这种可能性一致,我们还观察到在联合处理的细胞中 p62SQSTM1 的增加。然而,这些细胞中的自噬似乎是正常的,因为存在 LC3BII,并且自噬流似乎不受影响,如加入巴弗洛霉素 A₁ 所示。总之,这些数据表明,替皮芬尼通过诱导蛋白积累与硼替佐米协同作用,导致聚集物和自噬途径解偶联。